Pharmacokinetics of maropitant citrate in New Zealand White rabbits (Oryctolagus cuniculus)
- 1 October 2019
- journal article
- research article
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 80 (10) , 963-968
Abstract
OBJECTIVE: To determine the pharmacokinetics and adverse effects of maropitant citrate after IV and SC administration to New Zealand White rabbits (Oryctolagus cuniculus). ANIMALS: 11 sexually intact (3 males and 8 females) adult rabbits. PROCEDURES: Each rabbit received maropitant citrate (1 mg/kg) IV or SC. Blood samples were collected at 9 (SC) or 10 (IV) time points over 48 hours. After a 2-week washout period, rabbits received maropitant by the alternate administration route. Pharmacokinetic parameters were calculated. Body weight, food and water consumption, injection site, mentation, and urine and fecal output were monitored. RESULTS: Mean ± SD maximum concentration after SC administration was 14.4 ± 10.9 ng/mL and was detected at 1.25 ± 0.89 hours. Terminal half-life after IV and SC administration was 10.4 ± 1.6 hours and 13.1 ± 2.44 hours, respectively. Bioavailability after SC administration was 58.9 ± 13.3%. Plasma concentration at 24 hours was 2.87 ± 1.69 ng/mL after IV administration and 3.4 ± 1.2 ng/mL after SC administration. Four rabbits developed local dermal reactions at the injection site after SC injection. Increased fecal production was detected on the day of treatment and 1 day after treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Plasma concentrations of rabbits 24 hours after SC and IV administration of maropitant citrate (1 mg/kg) were similar to those of dogs at 24 hours. Reactions at the SC injection site were the most common adverse effect detected. Increased fecal output may suggest an effect on gastrointestinal motility. Additional pharmacodynamic and multidose studies are needed.Keywords
This publication has 18 references indexed in Scilit:
- Tachykinins and Their Receptors: Contributions to Physiological Control and the Mechanisms of DiseasePhysiological Reviews, 2014
- Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphoneVeterinary Anaesthesia and Analgesia, 2013
- The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive daysJournal of Veterinary Pharmacology and Therapeutics, 2012
- Efficacy of Maropitant in the Prevention of Delayed Vomiting Associated with Administration of Doxorubicin to DogsJournal of Veterinary Internal Medicine, 2010
- Safety, pharmacokinetics and use of the novel NK‐1 receptor antagonist maropitant (CereniaTM) for the prevention of emesis and motion sickness in catsJournal of Veterinary Pharmacology and Therapeutics, 2008
- The pharmacokinetics of maropitant, a novel neurokinin type‐1 receptor antagonist, in dogsJournal of Veterinary Pharmacology and Therapeutics, 2007
- Efficacy of injectable maropitant (Cerenia™) in a randomized clinical trial for prevention and treatment of cisplatin‐induced emesis in dogs presented as veterinary patientsVeterinary and Comparative Oncology, 2007
- Peristalsis regulation by tachykinin NK1receptors in the rabbit isolated distal colonAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2003
- NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pigPharmacology Biochemistry and Behavior, 2003
- Effects of Tachykinin NK1 Receptor Antagonists on the Viscerosensory Response Caused by Colorectal Distention in RabbitsThe Journal of Pharmacology and Experimental Therapeutics, 2002